Genetic susceptibility for DILI identified in GWASs
| Drug studied | Cohort (ethnicity) | Association described | SNP (gene)109 | OR |
|---|---|---|---|---|
| Ximelagatran110 thrombin inhibitor | 74 cases, 130 T controls (European) | HLA-DRB1*07 | HLA-DRB1 | 4.4 |
| Flucloxacillin111 β-lactam antibiotic | 51 cases, 282 P controls (European) | HLA-B*5701 | rs2395029 HCP5 | 45.0 |
| ST6GAL1 | rs10937275 ST6GAL1 | 4.1 | ||
| OR5H2 | rs1497546 OR5H8P—OR5K4 | 6.6 | ||
| ALG10B | rs6582630 ALG10B—CPNE8 | 2.8 | ||
| MCTP2 | rs4984390 MCTP2 | 3.3 | ||
| C9orf82 (CAAP1) | rs10812428 FAM71BP1—CAAP1 | 2.9 | ||
| Lumiracoxib112 Cyclo-oxygenase-2 inhibitor | 41 cases, 176 T controls; Replic: 24 cases (European†) | HLA-DRB1 | rs3129900 C6orf10 | 7.5 |
| Lapatinib113 kinase inhibitor | 37 cases, 1071 T controls, (European†) | HLA-DRB1*0701 Perfect linkage disequilibrium with DQA1*0201 | NR | NR |
| Lapatinib114 kinase inhibitor | 34 cases, 810 T controls, (European†) | HLA-DRB1*0701 | NR | NR |
| Amoxicillin-clavulanate115 antibiotic | 201 cases, 532 P controls (European) | HLA-DQB1*0602 | rs9274407 HLA-DQB1 | 3.1 |
| HLA-A*0201 | rs2523822 TRNAI25 | 2.3 | ||
| Multiple (Diclofenac116 non-steroidal anti-inflammatory drug) | 783 cases (30 diclofenac) 3001 P controls (European) | PPARG‡ | rs17036170 PPARG | 11.3 |
| Multiple (Flupirtine117 non-opioid analgesic) | 614 cases (6 flupirtine) 10 588 P controls (European) | HLA-DRB1*16:01-DQB1*05:02 | HLA-DRB1 | 18.7 |
| Multiple118 | 862 cases (21 terbinafine; 7 fenofibrate; 5 ticlopidine cases) 10 588 P controls (European) | HLA-A*33:01 | rs114577328 | 40.5; 58.7; 163.1 |
| Minocycline antibiotic119 | 25 cases 10 588 P controls (European) | HLA-B*35:02 | HLA-B*35:02 | 29.6 |
†Predominantly.
‡Associated with diclofenac DILI only.
DILI, drug-induced liver injury; GWASs, genome-wide association studies; NR, not reported; P, population control group; Replic, replication cohort; SNP, single nucleotide polymorphism; T, treated control group.